# 9lione

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/9lione

- Industry: Healthcare IT
- Headquarters: Japan
- Website: www.9lione.net
- Total disclosed funding: $0.8M
- Latest round: Series A (Sep 11, 2026)
- Investors on record: 6

## About

Based in Nerima-ku, Tokyo, Japan, 9lione, Inc. was founded in 2018 by Yusho Hirota and operates a licensed pharmaceutical wholesale and distribution-improvement DX platform that moves surplus medicines held by medical institutions and pharmacies to institutions facing shortages. As of September 2026, the company is led by its CEO, Yusho Hirota. On 11 September 2026, the company completed a Series A round of JPY 120 million led by Yokohama Capital as lead investor, with participation from Incubate Fund, DG Ventures, Mitsui Sumitomo Insurance Capital, Globe Advisors, NanoBank and Individual Investor, in the form of equity, bringing cumulative funding to JPY 440 million and funding expansion of its distribution platform. The company operates two current offerings. 9lione Cloud is a cloud pharmaceutical inventory-management system for medical institutions and pharmacies that provides prescription OCR capture from a tablet or smartphone including handwritten prescriptions, GS1-code reading without a dedicated barcode reader, automatic creation and updating of inventory lists, automatic drug-price revision updates, consumption-based order forecasting and a lending and sales ledger for transactions with nearby pharmacies. 9lione Platform enables institutions to sell surplus in-house medicines and to procure hard-to-obtain pharmaceuticals; the company holds a pharmaceutical wholesale license and takes the stock onto its own books, handling quality control, traceability and delivery under Japan's Pharmaceutical and Medical Device Act and GDP standards rather than acting only as a matching marketplace. The company earns revenue from a per-store monthly subscription charge for its cloud pharmaceutical-management service, offered from a free trial tier, and from acting as a licensed pharmaceutical wholesaler that holds inventory on its own account and completes the purchase and sale of surplus and hard-to-obtain medicines between medical institutions. The company plans to use its September 2026 Series A funding to expand its network of logistics and sales bases for nationwide coverage of medical institutions, to develop products for medical institutions including AI-based inventory visualization and transaction automation, and to strengthen its organization through recruitment in pharmaceutical affairs, product management, engineering and corporate functions. It is also developing AI supply-and-demand forecasting to deliver stable supply at appropriate prices.

## Funding rounds

- Series A, Sep 11, 2026, $0.8M — Mitsui Sumitomo Insurance Venture Capital, Incubate Fund, DG Ventures, Yokohama Capital, Globe advisors, Nanobank

## Investors

- Mitsui Sumitomo Insurance Venture Capital (https://capitalatlas.ai/funds/mitsui-sumitomo-insurance-venture-capital) — Series A
- Incubate Fund (https://capitalatlas.ai/funds/incubate-fund) — Series A
- DG Ventures (https://capitalatlas.ai/funds/dg-ventures) — Series A
- Yokohama Capital (https://capitalatlas.ai/funds/yokohama-capital) — Series A
- Globe advisors — Series A
- Nanobank — Series A